TNBC is a good candidate for immunotherapeutic treatments, primarily because of tumor immune infiltration, neoantigens caused by higher genomic instability, and mutational burden, as well as high expression levels of immune checkpoint markers such as programmed cell death ligand 1 (PD-L1) and programmed cell death protein 1 (PD-1) [24]. The gene discussed is PDCD1; the disease is neoplasm.